OncoMatch/Clinical Trials/NCT06651853
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Is NCT06651853 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab for diffuse large b-cell lymphoma.
Treatment: Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab — To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Excluded: MS4A1 loss of expression
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: systemic therapy — first-line
Patients who have failed first-line standard treatment (patients with relapsed disease < 12 months or primary refractory disease, or relapsed disease > 12 months but are transplant-ineligible after 1 line of systemic therapy, or relapsed disease after 2+ lines of therapy)
Cannot have received: bispecific antibody
Participants must not have received bispecific antibody therapy in the past
Cannot have received: anti-hematologic malignancy treatment
Participants have received anti-hematologic malignancy treatment within 2 weeks before the start of treatment or within 5 half-lives of the drug, whichever is longer
Cannot have received: large fraction radiation therapy
Exception: allowed if >4 weeks before first treatment and no radiation-related toxic reactions, no need for glucocorticoids, excluding radiation pneumonia, hepatitis, enteritis, etc.
Large fraction radiation therapy received within 4 weeks prior to the first treatment. For patients who received radiation therapy more than 4 weeks before the first treatment, all the following conditions must be met to be included: there are currently no radiation-related toxic reactions, no need to take glucocorticoids, excluding radiation pneumonia, radiation hepatitis, radiation enteritis, etc.
Cannot have received: traditional Chinese medicine with anti-tumor indications
Traditional Chinese medicine with anti-tumor indications received within 2 weeks before the first administration
Cannot have received: other clinical trial treatment
Treatment in another clinical trial within 4 weeks before the first administration
Lab requirements
Blood counts
Platelet count ≥30 x 10^9/L; absolute neutrophil count ≥1.0 x 10^9/L; good coagulation function (INR or PT ≤1.5× ULN)
Kidney function
Blood creatinine ≤1.5× ULN and creatinine clearance rate ≥60 ml/min
Liver function
Total bilirubin ≤1.5× ULN; AST and ALT ≤2.5× ULN
laboratory criteria: (1) Total bilirubin ≤1.5× ULN; (2) AST and ALT ≤2.5× ULN; (3) Blood creatinine ≤1.5× ULN and creatinine clearance rate ≥60 ml/min; (4) Good coagulation function, defined as INR or PT ≤1.5× ULN. Bone marrow insufficiency defined by platelet count <30 x 10^9/L or ANC <1.0 x 10^9/L [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06651853 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bispecific antibody, anti-hematologic malignancy treatment, large fraction radiation therapy disqualifies patients from enrollment.
Are patients with MS4A1 alterations eligible?
No. MS4A1 loss of expression is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify